MAGI2 and breast cancer: The results show that, compared with healthy controls, MAGI2-AS3 in PBMCs of breast cancer patients is significantly downregulated, which is consistent with its expression pattern in cancer tissues (Xue et al., 2021; Yang et al., 2018).